Dyne Therapeutics, Inc. (DYN) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Waltham, MA, United States. The current CEO is John G. Cox.
DYN has IPO date of 2020-09-17, 192 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $3.27B.
Dyne Therapeutics, Inc. is a biotechnology company focused on developing disease-modifying therapeutics for genetically driven muscle diseases. The company leverages its proprietary FORCE platform to advance treatment programs for myotonic dystrophy type 1, Duchenne muscular dystrophy, facioscapulohumeral dystrophy, and other rare skeletal, cardiac, and metabolic muscle diseases. Founded in 2017 and headquartered in Waltham, Massachusetts, Dyne operates primarily in the United States market, addressing significant unmet medical needs in the muscle disease therapeutic space.
